Vyne Therapeutics Inc

Vyne Therapeutics operates with a strong liquidity position, as evidenced by its cash and equivalents of $24.03 million, which significantly exceeds its total liabilities of $2.395 million, resulting in a current ratio of 12.53. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure with no leverage. The company's market cap of $21.37 million is significantly lower than its book value, as reflected in a price-to-book ratio of 0.77. The company is currently unprofitable, with a net loss of $26.48 million and an operating loss of $29.75 million in the latest reporting period. Its return on equity (ROE) is -9.54%, and its return on assets (ROA) is -8.78%, both of which are significantly below the industry median for biotechnology firms. The company's operating cash flow is negative at -$33.12 million, and its free cash flow is -$26.71 million, indicating that it is not generating positive cash from operations. Vyne Therapeutics does not disclose segment or geographic revenue breakdowns in its latest financials, and no material revenue concentration is reported. The company's operations are primarily focused on research and development, with no disclosed revenue-generating products or services in the current period. The company's growth trajectory is not yet defined in terms of revenue, as it has not yet achieved positive revenue growth. The company's current revenue is $570,000, and no forward-looking revenue guidance is provided in the latest filings. Analysts have assigned a mean price target of $2.00, with a median of $2.00 and a high of $2.00, suggesting a potential upside of 212% from the current market price of $0.64. Vyne Therapeutics is currently assessed as having low liquidity and dilution risk, with no immediate filing-based flags detected. The company has not issued any new shares in the latest period, and its basic and diluted share counts are identical at 33.32 million shares. No dilution adjustments are applied in the valuation snapshot, and the company's capital structure remains unchanged. No recent filings or transcripts are available in the provided data to indicate material events or strategic shifts in the company's operations. The company's financials suggest a continued focus on R&D with no immediate commercialization of products.